170 related articles for article (PubMed ID: 6870293)
1. [Development of antitumor agents: retrospection and perspective].
Sakurai Y
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1087-93. PubMed ID: 6870293
[TBL] [Abstract][Full Text] [Related]
2. Screening and evaluation of anticancer agents.
Zee-Cheng RK; Cheng CC
Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
[TBL] [Abstract][Full Text] [Related]
3. The preclinical new drug research program of the National Cancer Institute.
Driscoll JS
Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
[TBL] [Abstract][Full Text] [Related]
4. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
5. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
6. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
7. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
8. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
Suggitt M; Bibby MC
Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
[TBL] [Abstract][Full Text] [Related]
9. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
10. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
12. [Application of nude mouse-human cancer xenograft system for sensitivity test of anticancer drugs].
Fujita M; Taguchi T
Gan To Kagaku Ryoho; 1982 Apr; 9(4):606-15. PubMed ID: 7184418
[TBL] [Abstract][Full Text] [Related]
13. [Strategies for studies on mechanism of action of antineoplastic agents].
Kuśnierczyk H
Postepy Hig Med Dosw; 1995; 49(1):85-96. PubMed ID: 8657622
[TBL] [Abstract][Full Text] [Related]
14. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
Kelland LR
Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
16. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.
Peterson JK; Houghton PJ
Eur J Cancer; 2004 Apr; 40(6):837-44. PubMed ID: 15120039
[TBL] [Abstract][Full Text] [Related]
17. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
18. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
19. The NCI Developmental Therapeutics Program.
Collins JM
Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
[No Abstract] [Full Text] [Related]
20. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.
Fry DW; Kraker AJ; Connors RC; Elliott WL; Nelson JM; Showalter HD; Leopold WR
Anticancer Drug Des; 1994 Aug; 9(4):331-51. PubMed ID: 7916900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
